

Letters

RESEARCH LETTER

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

An epidemic of respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in China and has spread to other countries.¹ Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) of nasopharyngeal swabs typically has been used to confirm the clinical diagnosis.² However, whether the virus can be detected in specimens from other sites, and therefore potentially transmitted in other ways than by respiratory droplets, is unknown.

Methods | We investigated the biodistribution of SARS-CoV-2 among different tissues of inpatients with coronavirus disease 2019 (COVID-19) diagnosed based on symptoms and radiology and confirmed by SARS-CoV-2 detection. This study was approved by the ethics commissions of the participating hospitals, with a waiver of informed consent.

Patients with specimens collected based on clinical indications from 3 hospitals in the Hubei and Shandong provinces and Beijing, China, from January 1 through February 17, 2020, were included. Pharyngeal swabs were collected from most patients 1 to 3 days after hospital admission. Blood, sputum, feces, urine, and nasal samples were collected throughout the illness. Bronchoalveolar lavage fluid and fibrobronchoscope brush biopsy were sampled from patients with severe illness or undergoing mechanical ventilation. RNA was extracted from clinical specimens and determined by rRT-PCR targeting the open reading frame *1ab* gene of SARS-CoV-2 as previously described.² The cycle threshold values of rRT-PCR were used as indicators of the copy number of SARS-CoV-2 RNA in specimens with lower cycle threshold values corresponding to higher viral copy numbers. A cycle threshold value less than 40 is interpreted as positive for SARS-CoV-2 RNA. Four SARS-CoV-2 positive fecal specimens with high copy numbers were cultured, and then electron microscopy was performed to detect live virus. Patterns in a subgroup of patients with multiple specimens collected during hospitalization were explored.

Results | There were 1070 specimens collected from 205 patients with COVID-19 who were a mean age of 44 years (range, 5-67 years) and 68% male. Most of the patients presented with fever, dry cough, and fatigue; 19% of patients had severe illness. Bronchoalveolar lavage fluid specimens showed the highest positive rates (14 of 15; 93%), followed by sputum (72 of 104; 72%), nasal swabs (5 of 8; 63%), fibrobronchoscope brush biopsy (6 of 13; 46%), pharyngeal swabs (126 of 398; 32%), feces (44 of 153; 29%), and blood (3 of 307; 1%). None of the 72 urine specimens tested positive (Table).

The mean cycle threshold values of all specimen types were more than 30 ($<2.6 \times 10^4$ copies/mL) except for nasal swabs with a mean cycle threshold value of 24.3 (1.4×10^6 copies/mL), indicating higher viral loads (Table).

Twenty patients had 2 to 6 specimens collected simultaneously (Figure). Viral RNA was detected in single specimens from 6 patients (respiratory specimens, feces, or blood), while 7 patients excreted virus in respiratory tract specimens and in feces (n = 5) or blood (n = 2). Live SARS-CoV-2 was observed in the stool sample from 2 patients who did not have diarrhea.

Discussion | In this study, SARS-CoV-2 was detected in specimens from multiple sites of 205 patients with COVID-19, with lower respiratory tract samples most often testing positive for the virus. Importantly, the live virus was detected in feces, implying that SARS-CoV-2 may be transmitted by the fecal route. A small percentage of blood samples had positive PCR test results, suggesting that infection sometimes may be systemic. Transmission of the virus by respiratory and extra-respiratory routes may help explain the rapid spread of disease. In addition, testing of specimens from multiple sites may improve the sensitivity and reduce false-negative test results. Two smaller studies reported the presence of SARS-CoV-2 in anal or oral swabs and blood from 16 patients in Hubei Province,³ and viral load in throat swabs and sputum from 17 confirmed cases.⁴


The limitations of this study include that some patients did not have detailed clinical information available, so the data could not be correlated with symptoms or disease course and that the number of some types of samples was

Table. Detection Results of Clinical Specimens by Real-Time Reverse Transcriptase-Polymerase Chain Reaction

Specimens and values	Bronchoalveolar lavage fluid (n = 15)	Fibrobronchoscope brush biopsy (n = 13)	Sputum (n = 104)	Nasal swabs (n = 8)	Pharyngeal swabs (n = 398)	Feces (n = 153)	Blood (n = 307)	Urine (n = 72)
Positive test result, No. (%)	14 (93)	6 (46)	75 (72)	5 (63)	126 (32)	44 (29)	3 (1)	0
Cycle threshold, mean (SD)	31.1 (3.0)	33.8 (3.9)	31.1 (5.2)	24.3 (8.6)	32.1 (4.2)	31.4 (5.1)	34.6 (0.7)	ND
Range	26.4-36.2	26.9-36.8	18.4-38.8	16.9-38.4	20.8-38.6	22.3-38.4	34.1-35.4	
95% CI	28.9-33.2	29.8-37.9	29.3-33.0	13.7-35.0	31.2-33.1	29.4-33.5	0.0-36.4	

Abbreviation: ND, no data.

Figure. Severe Acute Respiratory Syndrome Coronavirus 2 Distribution and Shedding Patterns Among 20 Hospitalized Patients



small. Further investigation of patients with detailed temporal and symptom data and consecutively collected specimens from different sites is warranted.

Wenling Wang, PhD
Yanli Xu, MD
Ruqin Gao, MD
Roujian Lu, MPH
Kai Han, BS
Guizhen Wu, MD
Wenjie Tan, MD, PhD

Author Affiliations: National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China (Wang, Lu, Wu, Tan); Beijing Ditan Hospital, Capital Medical University, Beijing, China (Xu, Han); Qingdao Municipal Center for Disease Control and Prevention, Qingdao, China (Gao).

Accepted for Publication: March 5, 2020.

Corresponding Author: Wenjie Tan, MD, PhD, National Institute for Viral Disease Control and Prevention, China CDC, 155 Changbai Rd, Changping District, Beijing 102206, China (tanwj@ivdc.chinacdc.cn).

Published Online: March 11, 2020. doi:10.1001/jama.2020.3786

Author Contributions: Drs Wang and Tan had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Wang and Xu contributed equally.

Concept and design: Wang, Xu, Wu, Tan.

Acquisition, analysis, or interpretation of data: Xu, Gao, Lu, Han, Tan.

Drafting of the manuscript: Wang, Xu, Gao, Han, Tan.

Critical revision of the manuscript for important intellectual content: Xu, Lu, Wu, Tan.

Statistical analysis: Wang.

Obtained funding: Wang, Tan.

Administrative, technical, or material support: Xu, Gao, Lu, Han, Wu.

Supervision: Xu, Wu, Tan.

Conflict of Interest Disclosures: None reported.

Funding/Support: This work was supported by grants 2016YFD0500301 and 2020YFC0840900 from the National Key Research and Development Program of China and 2018ZX10101002 from the National Major Project for Control and Prevention of Infectious Disease in China.

Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Gary Wong, PhD (CAS Key Laboratory of Molecular Virology & Immunology, Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China) for English revision of the manuscript, and clinical staff members in hospitals in Hubei Province, Shandong Province,

and Beijing for collection of specimens. None of these individuals received compensation for their contributions.

1. Tan W, Zhao X, Ma X, et al. Notes from the field: a novel coronavirus genome identified in a cluster of pneumonia cases—Wuhan, China 2019-2020. *China CDC Weekly*. 2020;2(4):61-62.

2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. Published February 7, 2020. doi:10.1001/jama.2020.1585

3. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerg Microbes Infect*. 2020;9(1):386-389. doi:10.1080/22221751.2020.1729071

4. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. *Lancet Infect Dis*. Published online February 24, 2020. doi:10.1016/S1473-3099(20)30113-4

Ethics Committee Reviews of Applications for Research Studies at 1 Hospital in China During the 2019 Novel Coronavirus Epidemic

Since December 2019, an epidemic of coronavirus disease 2019 (COVID-19) has spread rapidly from Wuhan, Hubei Province, China.¹ As of March 7, there were 1272 confirmed coronavirus cases in Henan Province (the third-highest in China), which adjoins Hubei Province. Due to the high contagiousness of COVID-19 and the current lack of any effective vaccine or drug, scientists and physicians are conducting a series of clinical studies involving affected patients. In 2016, the World Health Organization (WHO) published “Guidance for Managing Ethical Issues in Infectious Disease”² to ensure the scientific validity of and participants’ rights and safety in studies conducted during outbreaks. The guidance stated that there is a moral obligation to conduct timely scientific research. The Ethics Committee of the Henan Provincial People’s Hospital reviewed the COVID-19 studies from the hospital based on those guidelines.

Methods | Henan Provincial People’s Hospital is a designated hospital for COVID-19. The ethics committee designed a review system for research proposals at the beginning of the epidemic, including the use of emergency video conference to review batches of project applications. Electronic documents were formally reviewed by the secretary and sent to members of the committee to review in advance of the